Perimetric and retinal nerve fiber layer findings in patients with Parkinsons disease

BMC Ophthalmology

Volumn 12, Issue 1, 2012, Pages

  Tsironi, Evangelia E ^a   Dastiridou, Anna ^a   Katsanos, Andreas ^a   Dardiotis, Efthymios ^a   Veliki, Stella ^a   Patramani, Gianna ^a   Zacharaki, Fani ^a   Ralli, Stella ^a   Hadjigeorgiou, Georgios M ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Parkinson's disease; Retina; Visual fields; Visual loss; Visual processing

Indexed keywords

ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GREECE; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; MALE; METHODOLOGY; MIDDLE AGED; NERVE FIBER; OPTICAL COHERENCE TOMOGRAPHY; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PERIMETRY; PHYSIOLOGY; RETINA GANGLION CELL; RETROSPECTIVE STUDY; RISK FACTOR; VISUAL DISORDER; VISUAL FIELD;

CROSS-SECTIONAL STUDIES; FEMALE; GREECE; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; NERVE FIBERS; PARKINSON DISEASE; RETINAL GANGLION CELLS; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VISION, LOW; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84866786900     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-12-54     Document Type: Article

References (41)

1. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Chaudhuri KR, Schapira AH, Lancet Neurol 2009 8 464 474 10.1016/S1474-4422(09)70068-7 19375664
2. Impairment of high-contrast visual acuity in Parkinson's disease. Jones RD, Donaldson IM, Timmings PL, Mov Disord 1992 7 232 238 10.1002/mds.870070308 1620141
3. Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease. Silva MF, Faria P, Regateiro FS, Forjaz V, Januário C, Freire A, et al. Brain 2005 128 2260 2271 10.1093/brain/awh581 16000338 (Pubitemid 41407966)
4. Visual dysfunction in Parkinson's disease Loss in spatiotemporal contrast sensitivity. Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M, Brain 1987 110 1675 1698 10.1093/brain/110.6.1675 3427405
5. Visual symptoms in Parkinson's disease. Armstrong RA, Parkinsons Dis 2011 2011 908306 21687773
6. The retina in Parkinson's disease. Archibald NK, Clarke MP, Mosimann UP, Burn DJ, Brain 2009 132 1128 1145 10.1093/brain/awp068 19336464
7. Dopamine and retinal function. Witkovsky P, Doc Ophthalmol 2004 108 17 40 15104164 (Pubitemid 38461014)
8. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Nguyen-Legros J, Surg Radiol Anat 1988 10 137 144 10.1007/BF02307822 3135618
9. Decreased dopamine in the retinas of patients with Parkinson's disease. Harnois C, Di Paolo T, Invest Ophthalmol Vis Sci 1990 31 2473 2475 2243012
10. Retinal nerve fiber layer thinning in Parkinson disease. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A, Vision Res 2004 44 2793 2797 10.1016/j.visres.2004.06.009 15342223 (Pubitemid 39165558)
11. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. Altintas O, Ieri P, Ozkan B, Calar Y, Doc Ophthalmol 2008 116 137 146 10.1007/s10633-007-9091-8 17962989 (Pubitemid 351279805)
12. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. Moschos MM, Tagaris G, Markopoulos I, Margetis I, Tsapakis S, Kanakis M, et al. Eur J Ophthalmol 2011 21 24 29 10.5301/EJO.2010.1318 20602324
13. In vivo retinal imaging by optical coherence tomography. Swanson EA, Izatt JA, Hee MR, Huang D, Lin CP, Schuman JS, et al. Opt Lett 1993 18 1864 1866 10.1364/OL.18.001864 19829430
14. Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Aaker GD, Myung JS, Ehrlich JR, Mohammed M, Henchcliffe C, Kiss S, Clin Ophthalmol 2010 4 1427 1432 21188154
15. Retinal thickness in Parkinson's disease. Archibald NK, Clarke MP, Mosimann UP, Burn DJ, Parkinsonism Relat Disord 2011 17 431 436 10.1016/j.parkreldis.2011.03.004 21454118
16. Optical coherence tomography in parkinsonian syndromes. Albrecht P, Müller AK, Südmeyer M, Ferrea S, Ringelstein M, Cohn E, et al. PLoS One 2012 7 4 34891 Epub 2012 Apr 13 10.1371/journal.pone.0034891
17. Visual field analysis in patients with Parkinson's disease. Yenice O, Onal S, Midi I, Ozcan E, Temel A, I-Gunal D, Parkinsonism Relat Disord 2008 14 193 198 10.1016/j.parkreldis.2007.07.018 17888714 (Pubitemid 351458421)
18. Diagnostic criteria for Parkinson disease. Gelb DJ, Oliver E, Gilman S, Arch Neurol 1999 56 33 39 10.1001/archneur.56.1.33 9923759 (Pubitemid 29046907)
19. Multifocal objective perimetry in the detection of glaucomatous field loss. Goldberg I, Graham SL, Klistorner AI, Am J Ophthalmol 2002 133 29 39 10.1016/S0002-9394(01)01294-6 11755837 (Pubitemid 34076501)
20. People and eyes: statistical approaches in ophthalmology. Murdoch IE, Morris SS, Cousens SN, Br J Ophthalmol 1998 82 971 973 10.1136/bjo.82.8.971 9828786 (Pubitemid 28408160)
21. The effect of levodopa and dopamine agonists on optic nerve head in Parkinson disease. Yavas GF, Yilmaz O, Küsbeci T, Oztürk F, Eur J Ophthalmol 2007 17 812 816 17932860
22. Inner retinal layer thinning in Parkinson disease. Hajee ME, March WF, Lazzaro DR, Wolintz AH, Shrier EM, Glazman S, et al. Arch Ophthalmol 2009 127 737 741 10.1001/archophthalmol.2009.106 19506190
23. Optical coherence tomography. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al. Science 1991 254 1178 1181 10.1126/science.1957169 1957169 (Pubitemid 21917444)
24. Imaging of the retinal nerve fibre layer with spectral domain optical coherence tomography for glaucoma diagnosis. Sung KR, Kim JS, Wollstein G, Folio L, Kook MS, Schuman JS, Br J Ophthalmol 2011 95 909 914 10.1136/bjo.2010.186924 21030413
25. Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. Wojtkowski M, Srinivasan V, Fujimoto JG, Ko T, Schuman JS, Kowalczyk A, et al. Ophthalmology 2005 112 1734 1746 10.1016/j.ophtha.2005.05.023 16140383 (Pubitemid 41400010)
26. In vivo human retinal imaging by ultrahigh-speed spectral domain optical coherence tomography. Nassif N, Cense B, Park BH, Yun SH, Chen TC, Bouma BE, et al. Opt Lett 2004 29 480 482 10.1364/OL.29.000480 15005199
27. Diagnostic ability of Fourier-domain vs time-domain optical coherence tomography for glaucoma detection. Sehi M, Grewal DS, Sheets CW, Greenfield DS, Am J Ophthalmol 2009 148 597 605 10.1016/j.ajo.2009.05.030 19589493
28. Sensitivity and specificity of time-domain versus spectral-domain optical coherence tomography in diagnosing early to moderate glaucoma. Chang RT, Knight OJ, Feuer WJ, Budenz DL, Ophthalmology 2009 116 2294 2299 10.1016/j.ophtha. 2009.06.012 19800694
29. Cirrus high-definition optical coherence tomography compared with Stratus optical coherence tomography in glaucoma diagnosis. Moreno-Montanes J, Olmo N, Alvarez A, Garcia N, Zarranz-Ventura J, Invest Ophthalmol Vis Sci 2010 51 335 343 10.1167/iovs.08-2988 19737881
30. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Bayer AU, Keller ON, Ferrari F, Maag KP, Am J Ophthalmol 2002 133 135 137 10.1016/S0002-9394(01) 01196-5 11755850 (Pubitemid 34076513)
31. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Bodis-Wollner I, Trends Neurosci 1990 13 296 302 10.1016/0166-2236(90)90113-O 1695407 (Pubitemid 20193462)
32. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Djamgoz MB, Hankins MW, Hirano J, Archer SN, Vision Res 1997 37 3509 3529 10.1016/S0042-6989(97)00129-6 9425527 (Pubitemid 27491631)
33. Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials. Peppe A, Stanzione P, Pierelli F, De Angelis D, Pierantozzi M, Bernardi G, Neurology 1995 45 1144 1148 10.1212/WNL.45.6.1144 7783879
34. Alteration of visual evoked potentials and electroretinograms in Parkinson's disease. Gottlob I, Schneider E, Heider W, Skrandies W, Electroencephalogr Clin Neurophysiol 1987 66 349 357 10.1016/0013-4694(87)90032- 0 2435514 (Pubitemid 17030599)
35. Visual contrast response functions in Parkinson's disease: evidence from electroretinograms, visually evoked potentials and psychophysics. Langheinrich T, Elst L, Tebartz V, Lagrèze WA, Bach M, Lücking CH, et al. Clin Neurophysiol 2000 111 66 74 10.1016/S1388-2457(99)00223-0 10656512
36. Visual evoked cortical potentials and pattern electroretinograms in Parkinson's disease and control subjects. Nightingale S, Mitchell KW, Howe JW, J Neurol Neurosurg Psychiatry 1986 49 1280 1287 10.1136/jnnp.49.11.1280 3794734 (Pubitemid 17174030)
37. Measurements of visual evoked potentials in Parkinson's disease. Bodis-Wollner I, Yahr MD, Brain 1978 101 661 671 10.1093/brain/101.4.661 737524 (Pubitemid 9051163)
38. Oculomotor abnormalities in Parkinson's disease. Shibasaki H, Tsuji S, Kuroiwa Y, Arch Neurol 1979 36 360 364 10.1001/archneur.1979.00500420070009 454234 (Pubitemid 9150283)
39. Between-algorithm, between-individual differences in normal perimetric sensitivity: full threshold, FASTPAC, and SITA. Swedish Interactive Threshold algorithm. Wild JM, Pacey IE, Hancock SA, Cunliffe IA, Invest Ophthalmol Vis Sci 1999 40 1152 1161 10235548 (Pubitemid 29211452)
40. A new generation of algorithms for computerized threshold perimetry, SITA. Bengtsson B, Olsson J, Heijl A, Rootzén H, Acta Ophthalmol Scand 1997 75 368 375 9374242 (Pubitemid 27470462)
41. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, et al. Neurology 2010 9 75 1717 1725